We claim:

- An oral matrix pharmaceutical composition comprising doxazosin or a
 pharmaceutically acceptable salt thereof, a low viscosity release retarding agent and
 a high viscosity release retarding agent.
- The composition of claim 1, wherein the release retarding agents include one or more of cellulose derivatives, acrylic acid or methacrylate polymers/copolymers, gums, vinyl alcohol or vinylpyrrolidone based polymers, block copolymers, or polyethylene oxide.
- 3. The composition of claim 2, wherein the cellulose derivatives comprise one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, or methylcellulose.
- 4. The composition of claim 1, wherein the low viscosity release retarding agent comprises between about 5% to about 40% w/w of the composition.
- 5. The composition of claim 1, wherein the low viscosity release retarding agent comprises between about 8% to about 25% w/w of the composition.
- 6. The composition of claim 1, wherein the high viscosity release retarding agent comprises between about 5% to about 40% w/w of the composition.
- 7. The composition of claim 1, wherein the high viscosity release retarding agent comprises between about 8% to about 20% w/w of the composition.
- 8. The composition of claim 1, further comprising one or more solubility enhancers.
- 9. The composition of claim 8, wherein the one or more solubility enhancers comprises one or more of polyethylene glycols, surfactants, propylene glycol, glycerol, monoalcohols, higher alcohols, DMSO, dimethylformamide, N, N-dimethylacetamide, 2-pyrrolidone; N-(2-hydroxyethyl) pyrrolidone, N-methylpyrrolidone, 1-dodecylazacycloheptan-2-one and other n-substituted-alkyl-azacycloalkyl--2-ones.
- 10. The composition of claim 1, further comprising one or more pharmaceutically acceptable excipients.
- 11. The composition of claim 10, wherein the one or more pharmaceutically acceptable excipients comprise one or more of binders, diluents and lubricant/glidants.

- 12. The composition of claim 1, wherein the composition is the form of tablets, capsules, pellets, granules or any other dosage forms suitable for oral administration.
- 13. The composition of claim 1, wherein the composition releases the doxazosin over a period of about 12 hours to about 24 hours.
- 14. An oral matrix pharmaceutical composition comprising doxazosin or its salt, solvate hydrate, enantiomers or mixture thereof, about 5% to about 40% w/w of hydroxypropylmethyl cellulose of high viscosity, about 5% to about 40% w/w of hydroxypropyl methylcellulose of low viscosity, about 2% to about 20% w/w of polyethylene glycol, about 15% to about 50% w/w of lactose, about 10% to about 50% w/w of microcrystalline cellulose, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.
- 15. An oral matrix pharmaceutical composition comprising doxazosin or a salt, solvate, hydrate, enantiomer or mixture thereof, about 8% to about 20% w/w of hydroxypropylmethyl cellulose of high viscosity, about 8% to about 25% w/w of hydroxypropyl methylcellulose of low viscosity, about 5% to about 10% w/w of polyethylene glycol, about 20% to about 40% w/w of lactose, about 20% to about 40% w/w of microcrystalline cellulose, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.
- 16. An oral matrix pharmaceutical composition comprising doxazosin or a salt, solvate, hydrate, enantiomer or mixture thereof, about 5% to about 40% w/w of hydroxypropyl methylcellulose of high viscosity, about 5% to about 40% w/w of hydroxypropyl methylcellulose of low viscosity, about 1% to about 20% w/w of sodium alginate and alginic acid, about 5% to about 20% of Eudragit EPO, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.
- 17. An oral matrix pharmaceutical composition comprising doxazosin or a salt, solvate, hydrate, enantiomer or mixture thereof, about 8% to about 20% w/w of hydroxypropyl methylcellulose of high viscosity, about 10% to about 25% w/w of hydroxypropyl methylcellulose of low viscosity, about 2% to about 10% w/w of

WO 2005/037247 PCT/IB2004/003378

16

- sodium alginate and alginic acid, about 6% to about 10% w/w of Eudragit EPO, about 0.1% to about 3% w/w of magnesium stearate, about 0.1% to about 2% w/w of talc and about 0.1% to about 3% w/w of colloidal silicon dioxide.
- 18. A method of treating one or more of hypertension, urinary outflow obstruction and symptoms associated with benign protastic hyperplasia in a patient in need thereof, the method comprising administering an oral matrix pharmaceutical composition comprising doxazosin or a pharmaceutically acceptable salt thereof, a low viscosity release retarding agent and a high viscosity release retarding agent.